As countries develop their health systems on the path to Universal Health Coverage (UHC) (#LeaveNoOneBehind), many countries are experimenting with the development of a health technology assessment (HTA) agency in order to set priorities for health benefit packages, make go/no go decisions about

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

\"First Step”, a program evaluation report, assessing HITAP’s two-year efforts and providing recommendations for further development of HITAP. This program evaluation was conducted by four external evaluators including Prof. John Cairns, Dr. Kalipso Chalkidou, Prof. Paibul Suriyawongpaisal, and Dr. Jirawat Panpiemras. Moreover, Prof. Mark Sculp

Since 2013, the HITAP International Unit (HIU) has been providing technical support to various developing countries such as Indonesia, Vietnam, Bhutan, and India by sharing the Thai experience in generating and using health technology assessment (HTA) to inform policy decisions. HITAP works in colla

As we approach the end of an unprecedented year, the approval of select COVID-19 vaccines by stringent regulatory authorities and programmatic roll-out has been cause for optimism. However, it is imperative to assure equitable access to those in need in all regions of the world as a core component o

On 2nd – 6th October 2023, HITAP hosted a topic selection workshop and communication training for relevant HTA stakeholders in Ghana, with the support of the Access and Delivery Partnership (ADP). This workshop was held with the aims to increase awareness of health technology ass

Bhutan is a rapidly growing economy that is transitioning from international donor support. As such, the country is looking for ways to ensure that they continue to provide the adequate services and support for their population in a rational and sustainable manner. Bhutan has begun using health tech

The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht for the CKD treatment and other related expenses.

Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,